(Q71688019)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

title

Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

Akakura K

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Akimoto S

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Ohki T

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Shimazaki J

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

language of work or name

English

0 references

publication date

1 April 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

700-4; discussion 704-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

20 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

The promoter of the prostate-specific antigen gene contains a functional androgen responsive element

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Therapy with progestational agents in advanced benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

An Inhibitory Effect of TZP-4238 on the Growth of Androgen-Sensitive Rat Prostatic Tumor (Dunning R3327)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Androgen receptor gene mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980070-3

7 January 2021

10.1016/S0090-4295(99)80070-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7536369%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference